The impact of CFTR modulator therapies on CF airway microbiology

Geraint B. Rogers, Steven L. Taylor, Lucas R. Hoffman, Lucy D. Burr

Research output: Contribution to journalReview articlepeer-review

24 Citations (Scopus)


Major historical advances in cystic fibrosis (CF) respiratory clinical care, including mechanical airway clearance and inhaled medications, have aimed to address the consequences of cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction. In contrast, CFTR modulator therapies instead target the underlying protein defect that leads to CF lung disease. The extent to which these therapies might reduce susceptibility to chronic lung infections remains to be seen. However, by improving airway clearance, reducing the requirement for antibiotics, and in some cases, through direct antimicrobial effects, CFTR modulators are likely to result in substantial changes in CF airway microbiology. These changes could contribute substantially to the clinical benefit associated with modulator therapies, as well as providing an important indicator of treatment efficacy and residual pathophysiology. Indeed, the widespread introduction of modulator therapies might require us to re-consider our models of CF airway microbiology.

Original languageEnglish
Article numberJCF-01859
Pages (from-to)359-364
Number of pages6
JournalJournal of Cystic Fibrosis
Issue number3
Publication statusPublished - May 2020


  • Airway microbiome
  • CFTR modulators
  • Lung infection


Dive into the research topics of 'The impact of CFTR modulator therapies on CF airway microbiology'. Together they form a unique fingerprint.

Cite this